RxSight RXST 深 沪
等待开盘 08-10 09:30:00 美东时间
6.26
+0.180
+2.96%
华盛通- 最 高6.43
- 今 开6.03
- 成交量 62.67万股
- 最 低 5.43
- 昨 收 6.08
- 总市值 17.22万
- 52周最高 13.22
- 市盈率 静 --
- 换手率 2278.45%
- 52周最低 4.48
- 委 比 12.54%
- 总股本 2.75万
- 历史最高 66.54
- 量 比 0.86
- 振 幅 16.45%
- 历史最低 1.10
- 每 手 1
- 风险率 2.04%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多RxSight Sees Q2 Sales $32.000M-$34.000M vs $32.077M Est
RxSight (NASDAQ:RXST) sees Q2 sales of $32.000 million-$34.000 million vs $32.077 million analyst estimate.
07-07 04:50
RxSight Sees Q2 Revenue Of $32M-$34M; Sees FY2026 Revenue Of $140M-$160M
RxSight, Inc. (NASDAQ:RXST) today announced select preliminary financial results for the second quarter of 2026 and updates to its standalone product pipeline, following the announcement of the company’s strategic
07-07 04:18
Gold Rises Sharply; Lyra Therapeutics Shares Plunge
U.S. stocks traded mixed midway through trading, with the Nasdaq Composite gain...
01-13 01:26
RxSight's CFO Shelley Thunen To Transition From Her Role
RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced that Shelley Thunen, the Company's Chief Financial
2025-12-23 06:16
Peeling Back The Layers: Exploring RxSight Through Analyst Insights
Ratings for RxSight (NASDAQ:RXST) were provided by 8 analysts in the past three...
2024-09-13 20:00
Needham Reiterates Buy on RxSight, Maintains $66 Price Target
Needham analyst David Saxon reiterates RxSight (NASDAQ:RXST) with a Buy and maintains $66 price target.
2024-09-13 18:40
Needham Raises Price Target on RxSight to $66 From $54, Adds Stock to Conviction List, Keeps Buy Rating
07:20 AM EDT, 08/20/2024 (MT Newswires) -- RxSight (RXST) has an average investment rating of buy among analysts polled by Capital IQ, with price targets ranging from $54 to $75. (MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia a...
2024-08-20 19:20
